Amarin Corp Plc (AMRN)

[ziploc_1]

Hickma is contesting the R-IT patent, which is the patent for Vascepa to be used as a treatment for CVD...Hickma's contention will be that the Jelis study made it obvious that Vascepa was a treatment to reduce CVD.

In 2013,at the FDA anchor hearing, a panel of experts decided that it was NOT obvious that Vascepa was useful for CVD and they voted to deny approval until completion of the R-It study...Only after the completion of this study did it become obvious that Vascepa was a treatment for CVD

Hickma is now running scared because the potential of the rule 60 and the infringement suits to be decided against them.

Hickma is using this frivolous assault on the '077' patent as a bargaining chip to induce Amarin to settle with them in case Hickma loses the other legal cases against them.

Hickma has declared war on Amarin ...this is another reason why Amarin must fight them by joining the rule 60 case.